1. Aptamers: ushering in new hopes in targeted glioblastoma therapy
   Debarpan Chatterjee et al, 2024, Journal of Drug Targeting CrossRef
2. Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell
   Luca Gambini et al, 2018, ACS Chemical Biology CrossRef
3. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
   Michael C. Burger et al, 2019, Frontiers in Immunology CrossRef
4. Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate
   Ahmed F. Salem et al, 2018, Journal of Medicinal Chemistry CrossRef
5. Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions
   Mingming Wang et al, 2023, Frontiers in Immunology CrossRef
6. Cross-Talk and Subset Control of Microglia and Associated Myeloid Cells in Neurological Disorders
   Jatia Mills et al, 2022, Cells CrossRef
7. Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
   Jun Hasegawa et al, 2016, Cancer Biology & Therapy CrossRef
8. Advanced T and Natural Killer Cell Therapy for Glioblastoma
   Wan-Soo Yoon et al, 2023, Journal of Korean Neurosurgical Society CrossRef
9. Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic
   Weijing Chu et al, 2023, Biomacromolecules CrossRef
10. The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
    Jill Wykosky et al, 2008, Molecular Cancer Research CrossRef